Michael S. Orr - Concepedia

Author

Michael S. Orr

Virginia Commonwealth University Medical Center

Also Known As

M S Orr, M. S. ORR, M. S. Orr, Michael Orr, Michael S Orr, Michael S. Orr, Michael Scott Orr

Publications

Citations

H-Index

Concepts

All Affiliations

Virginia Commonwealth University Medical Center United States Food and Drug Administration National Institutes of Health Agilent Technologies (United States)SAS Institute (United States)

About

Michael S. Orr is an author at Virginia Commonwealth University Medical Center specializing in medicine, breast cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	2.5K
2	Health Sciences	2	2	105
3	Engineering	1	1	2.2K
4	Social Sciences	1	1	15
5	Biostatistics	1	1	107

Michael S. Orr

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements Leming Shi, Leming Shi, Laura Reid, Nature Biotechnology BioinformaticsSystems BiologyGene Expression MeasurementsEngineeringMedicine	2006	2.2K
Evaluation of external RNA controls for the assessment of microarray performance Weida Tong, Anne Bergstrom Lucas, Richard Shippy, Nature Biotechnology Functional GenomicsGeneticsMicroarray PerformanceGene ExpressionTranscriptomics Technology	2006	107
Electronic cigarettes in the USA: a summary of available toxicology data and suggestions for the future: Table 1 Michael S. Orr Tobacco Control	2014	105
UCN-01 Abrogates G2 Arrest through a Cdc2-dependent Pathway That Is Associated with Inactivation of the Wee1Hu Kinase and Activation of the Cdc25C Phosphatase Lijia Yu, L. Orlandi, Pei Wang, Journal of Biological Chemistry	1998	99
Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Frank A. Fornari, W. David Jarvis, Steven Grant, PubMed Breast OncologyDna FragmentationCell ProliferationNm DoxorubicinCancer Biology	1994	84
Growth arrest and non-apoptotic cell death associated with the suppression of c-myc Expression in MCF-7 breast tumor cells following acute exposure to doxorubicin Frank A. Fornari, W. David Jarvis, Steven Grant, Biochemical Pharmacology Breast OncologyC-myc ExpressionAcute ExposureApoptosisImmunology	1996	74
Effects of c-erbB2 Overexpression on the Drug Sensitivities of Normal Human Mammary Epithelial Cells Michael S. Orr JNCI Journal of the National Cancer Institute	2000	36
Induction of DNA damage, inhibition of DNA synthesis and suppression of c- myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line David A. Gewirtz, Joyce K. Randolph, Juhi Chawla, Cancer Chemotherapy and Pharmacology Breast OncologyDna DamageOncogenic AgentDna SynthesisBreast Cancer	1998	26
Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells Roderick T. Bunch, Lawrence F. Povirk, Michael S. Orr, Biochemical Pharmacology Tumor BiologyBreast OncologyOncogenic AgentC-myc ExpressionBreast Cancer	1994	24
Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: evidence for induction of gene-specific damage and alterations in gene expression. David A. Gewirtz, Michael S. Orr, Frank A. Fornari, PubMed Breast OncologyC-myc ExpressionC-myc GeneMolecular BiologyCell Proliferation	1993	21

Page 1